Market Cap
$288.4M
SABS
SAB Biotherapeutics, Inc.
$2.97 ▼ -2.78%
Prev close $3.06Market cap$288.4M
12-mo target$11.64 (+291.1%)
High Impact Filing (7/10)14 New Institutional Positions5 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on SABS right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Inst. Holders
50 funds
Inst. Value
$125.2M
Inst. Activity
14 buys / 5 sells
Social Sentiment
50° Neutral
SEC Reports
3
Press Releases
5
Price chart 30d -20.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 short_volume
Short Volume: SABS — 82.9% short (0.6M / 0.7M)
Short: 573,202 | Exempt: 0 | TRF Vol: 691,396 | Short Ratio: 82.9% | Off-exchange volume (dark pool
Sep 17, 2026 Insider
Jul 7, 2026 SEC Kropotova Alexandra surrendered for taxes 473 shares
CHIEF MEDICAL OFFICER
SAB Biotherapeutics announced that Breakthrough T1D awarded a grant to support the PRISE-hATG study evaluating SAB-142 i
8-K — Impact 4/10
Jun 30, 2026 Inst.
ADAGE CAPITAL PARTNERS GP, — ADD
6,405,553 shares ($25.0M)
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
3,066,016 shares ($12.0M)
Jun 25, 2026 Insider
May 29, 2026 Press Kropotova Alexandra surrendered for taxes 988 shares
CHIEF MEDICAL OFFICER
SAB Biotherapeutics announced upcoming data presentations at the ADA and FOCIS conferences in June 2026, highlighting it
Impact 3/10
SAB Biotherapeutics reported Q1 2026 EPS of -$0.35, a 68.3% miss vs consensus of -$0.21, with net loss widening to $18.9
PRESS-RELEASE — Impact 7/10
Analyst ratings buy % +2.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jun 24, 2026 | Barclays | INITIATE | Overweight | 54% |
| Jun 17, 2026 | Chardan Capital | MAINTAIN | Buy | 49% |
| Jun 15, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
| Jun 15, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 22, 2026 | Citigroup | INITIATE | Buy | 55% |
| May 20, 2026 | Jefferies | INITIATE | Buy | 53% |
| May 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 11, 2026 | Rodman & Renshaw | REITERATE | Buy | 39% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Aug 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Jul 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Jun 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% |
Price targets
Where 11 covering analysts think SABS trades over the next 12 months.
$11.64 +291.1% upside Strong Buy
Current$2.98 Low$6.00 Median$12.00 High$16.00 11 analysts
$6.00$16.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 1 bullish, 2 bearish, 0 mixed, 0 neutral · avg impact 5.7/10.Plus 5 press releases.
BULLISH8-K4/10
SAB Biotherapeutics announced that Breakthrough T1D awarded a grant to support the PRISE-hATG study
Jul 7, 2026
BEARISHPRESS-RELEASE7/10
SAB Biotherapeutics reported Q1 2026 EPS of -$0.35, a 68.3% miss vs consensus of -$0.21, with net lo
May 12, 2026
BEARISH8-K6/10
SAB Biotherapeutics is conducting a public offering of 19.3 million shares of common stock and pre-f
Mar 19, 2026
NEUTRAL3/10
SAB Biotherapeutics announced upcoming data presentations at the ADA and FOCIS conferences in June 2
May 29, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
short_volume
Short Volume: SABS — 82.9% short (0.6M / 0.7M)
Short: 573,202 | Exempt: 0 | TRF Vol: 691,396 | Short Ratio: 82.9% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: SABS — 76.7% short (0.9M / 1.1M)
Short: 881,288 | Exempt: 0 | TRF Vol: 1,148,633 | Short Ratio: 76.7% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
routine
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
MIAMI, Sept. 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully hum
Aug 6, 2026
earnings
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
Over 60 clinical sites activated in registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes; Enrollment remains on track for co
Aug 6, 2026
earnings_calendar
SABS Q2 2026 Earnings Scheduled — 2026-08-06
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.27 | $-0.32–$-0.22 | — | +11.9% | 2↑ 0↓ | $0.0B | 5 |
| Next Q | $-0.27 | $-0.39–$-0.19 | 34.0% | +18.0% | 2↑ 0↓ | $0.0B | 5 |
| Current FY | $-1.16 | $-1.34–$-1.04 | -44.1% | +9.1% | 1↑ 0↓ | $0.0B | 5 |
| Next FY | $-0.95 | $-1.22–$-0.60 | 17.9% | +2.7% | 1↑ 0↓ | $0.0B | 5 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.269 | — |
| 7d ago | $-0.305 | +0.036 |
| 30d ago | $-0.305 | +0.036 |
| 60d ago | $-0.240 | -0.029 |
| 90d ago | $0.000 | -0.269 |
Institutional ownership
Which big funds own SABS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $125.2M total value (32,100,800 shares) as of 2026-Q2. Top holders: ADAGE, RA, BALYASNY. Net buying activity: 14 institutions added/increased vs 5 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 6,405,553 | $25.0M | 20.0% | ADD +88.1% |
| RA CAPITAL MANAGEMENT, L.P. | 4,401,500 | $17.2M | 13.7% | — |
| BALYASNY ASSET MANAGEMENT L.P. | 3,760,439 | $14.7M | 11.7% | DOUBLED +690.9% |
| BlackRock, Inc. | 3,066,016 | $12.0M | 9.6% | DOUBLED +917.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,972,929 | $11.6M | 9.3% | — |
| MILLENNIUM MANAGEMENT LLC | 2,749,087 | $10.7M | 8.6% | DOUBLED +835.8% |
| GEODE CAPITAL MANAGEMENT, LLC | 1,277,185 | $5.0M | 4.0% | DOUBLED +322.9% |
| Woodline Partners LP | 1,180,355 | $4.6M | 3.7% | TRIM -58.6% |
| Ensign Peak Advisors, Inc | 1,172,641 | $4.6M | 3.7% | — |
| AMERIPRISE FINANCIAL INC | 611,019 | $2.4M | 1.9% | TRIM -58.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | ADD | 3,405,553 | 6,405,553 | +88.1% | $25.0M |
| BlackRock, Inc. | DOUBLED | 301,326 | 3,066,016 | +917.5% | $12.0M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 302,036 | 1,277,185 | +322.9% | $5.0M |
| Woodline Partners LP | TRIM | 2,851,791 | 1,180,355 | -58.6% | $4.6M |
| AMERIPRISE FINANCIAL INC | TRIM | 1,476,106 | 611,019 | -58.6% | $2.4M |
| STATE STREET CORP | DOUBLED | 74,231 | 530,831 | +615.1% | $2.1M |
| VANGUARD FIDUCIARY TRUST CO | ADD | 197,619 | 373,980 | +89.2% | $1.5M |
| UBS Group AG | DOUBLED | 46,623 | 365,878 | +684.8% | $1.4M |
| NORTHERN TRUST CORP | DOUBLED | 57,426 | 362,489 | +531.2% | $1.4M |
| GOLDMAN SACHS GROUP INC | ADD | 113,940 | 191,305 | +67.9% | $746.1K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
5 insiders, 8 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | Kropotova Alexandra | CHIEF MEDICAL OFFICER | TAX W/H | 473 | — | — |
| Jun 25, 2026 | Kropotova Alexandra | CHIEF MEDICAL OFFICER | TAX W/H | 988 | — | — |
| Mar 24, 2026 | Kropotova Alexandra | CHIEF MEDICAL OFFICER | TAX W/H | 988 | — | — |
| Feb 3, 2026 | Sullivan Eddie Joe | PRESIDENT | AWARD | 3,000,000 | — | — |
| Feb 3, 2026 | Reich Samuel J | CEO | AWARD | 4,800,000 | — | — |
| Feb 3, 2026 | To Lucy | See Remarks | AWARD | 2,400,000 | — | — |
| Feb 3, 2026 | Bausch Christoph Lawrence | CHIEF OPERATING OFFICER | AWARD | 1,800,000 | — | — |
| Feb 3, 2026 | Kropotova Alexandra | CHIEF MEDICAL OFFICER | AWARD | 2,400,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SABS.
Shares short
3,603,065
Settlement Sep 15, 2026
Change vs prior
-12.6%
Semi-monthly cycle
Days to cover
13.4
At avg daily volume
Of shares outstanding
≈4.0%
Estimate — not % of float
All SABS filing & press-release reports (8)
- 8-K reportJul 7, 2026
- PRESS-RELEASE reportMay 29, 2026
- PRESS-RELEASE reportMay 12, 2026
- PRESS-RELEASE reportMar 19, 2026
- 8-K reportMar 19, 2026
- PRESS-RELEASE reportMar 18, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 10, 2026